Literature DB >> 1457190

The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants.

R Bomford1, M Stapleton, S Winsor, A McKnight, T Andronova.   

Abstract

Both saponin and muramyl dipeptide (MDP) formulated with a squalane-in-water emulsion of large particle size prepared with a vortex mixer were superior to Al(OH)3 as adjuvants for HIV gp120 in mice. All the adjuvants induced IgG1 antibody, but saponin elicited the highest titers of IgG2a. The secretion of interleukin-5 (IL-5) and interferon gamma (IFN gamma) by lymph node cells cultured in vitro with gp120 was studied. All the cultures secreted IL-5, but only those from saponin-immunized mice produced IFN gamma, suggesting that saponin is capable of activating both the Th1 and TH2 T-cell subsets. The titers of neutralizing antibodies were low with both MDP and saponin, and they occurred in mice which were also positive for antibodies against a V3 loop peptide. Glucosaminylmuramyl dipeptide (GMDP) which is less pyrogenic than MDP and a nonpyrogenic analog GMDPA, displayed equivalent adjuvant activity to MDP. The level and isotype composition of antibodies induced by GMDP in combination with squalane emulsions depended on the dimension of the emulsion particles. With a large (2500 nm) particle size the response was confined to IgG1 in Balb/c mice, but when this was reduced to 150 nm by sonication the antibody response was increased and relatively high levels of IgG2a appeared in some mice.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1457190     DOI: 10.1089/aid.1992.8.1765

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  8 in total

1.  Saponin adjuvant primes for a dominant interleukin-10 production to ovalbumin and to Trypanosoma cruzi antigen.

Authors:  C E Tadokoro; M S Macedo; I A Abrahamsohn
Journal:  Immunology       Date:  1996-11       Impact factor: 7.397

Review 2.  SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Authors:  Rajesh K Sharma; Esma S Yolcu; Haval Shirwan
Journal:  Expert Rev Vaccines       Date:  2014-03       Impact factor: 5.217

3.  Immunological detection of nitric oxide synthase(s) in human tissues using heterologous antibodies suggesting different isoforms.

Authors:  D R Springall; V Riveros-Moreno; L Buttery; A Suburo; A E Bishop; M Merrett; S Moncada; J M Polak
Journal:  Histochemistry       Date:  1992-11

4.  Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins.

Authors:  P Andersen
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

Review 5.  Vaccine delivery using nanoparticles.

Authors:  Anthony E Gregory; Richard Titball; Diane Williamson
Journal:  Front Cell Infect Microbiol       Date:  2013-03-25       Impact factor: 5.293

6.  Poliovirus-specific CD4+ Th1 clones with both cytotoxic and helper activity mediate protective humoral immunity against a lethal poliovirus infection in transgenic mice expressing the human poliovirus receptor.

Authors:  B P Mahon; K Katrak; A Nomoto; A J Macadam; P D Minor; K H Mills
Journal:  J Exp Med       Date:  1995-04-01       Impact factor: 14.307

7.  Adjuvant Immune Enhancement of Subunit Vaccine Encoding pSCPI of Streptococcus iniae in Channel Catfish (Ictalurus punctatus).

Authors:  Jie Jiang; Zonglin Zheng; Kaiyu Wang; Jun Wang; Yang He; Erlong Wang; Defang Chen; Ping Ouyang; Yi Geng; Xiaoli Huang
Journal:  Int J Mol Sci       Date:  2015-11-25       Impact factor: 5.923

8.  Ag85A DNA Vaccine Delivery by Nanoparticles: Influence of the Formulation Characteristics on Immune Responses.

Authors:  Johanna Poecheim; Christophe Barnier-Quer; Nicolas Collin; Gerrit Borchard
Journal:  Vaccines (Basel)       Date:  2016-09-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.